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Abstract
Since its discovery, elevated prostate-specific antigen (PSA) has been the measurement to 
indicate possibility of prostate cancer, as well as biochemical recurrence following treatment. 
Although PSA has led to decrease in prostate cancer–related mortalities, PSA is a nonspe-
cific prostate cancer biomarker reflective of other prostate-related conditions such as benign 
prostatic hyperplasia (BPH), resulting in a high false-positive rate. This has led to overtreat-
ment of men with clinically insignificant disease. While most prostate cancer patients have 
slowly progressive disease and should be treated conservatively, roughly 10% of patients 
will progress to have metastatic disease, of which the majority of prostate cancer deaths can 
be attributed. Stratifying these patients based on prognosis so that they may benefit from 
aggressive treatment is critical to their survival. Biomarkers for prostate cancer diagnosis 
and subsequent prognostic screening have significantly advanced this field. Here, we review 
some of the current blood, tissue, and urine biomarker tools used to measure an array of 
molecules including DNA, RNA, protein, or even epigenetic modifications. Utilizing the 
technologies described here, as well as looking to the future, correct early identification of 
prostate cancer with powerful prognostic value is much closer than ever before.
Keywords: prostate cancer, biomarker, early detection, prognosis, risk stratification
1. Introduction
Prostate cancer remains the most commonly diagnosed cancer in men in the United States 
with over 200,000 new cases detected annually [1]. Gleason grade of prostate cancer, devel-
oped by Dr. Donald Gleason in the 1960s, remains the most prognostic indicator of prostate 
cancer to date. Gleason grade ranges from 1 (normal) to 5 (most abnormal) and is assigned 
based on the histology of prostate tissues from biopsies. The Gleason score ranges from 2 
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to 10 and is the sum of the two most common Gleason grades. However, assessing Gleason 
grade requires invasive tissue biopsies. Less than one-third of men tested for prostate cancer 
through biopsy are diagnosed with cancer by histological analysis. Meanwhile a negative 
biopsy does little to reassure patients and clinicians of negative cancer status. This leads to a 
large number of patients undergoing painful initial biopsy procedures that may ultimately 
be repeated due to uncertainty of diagnosis [2]. Prostate cancer biopsies are a painful and 
invasive procedure, with the chance of complications including bleeding and infection [3–5].
Of those patients with positive diagnoses, roughly 10% will progress to metastatic prostate 
cancer, resulting in about 30,000 deaths annually in the United States. It is obvious that these 
patients should receive aggressive treatment at the earliest sign of disease. However there is 
concern as to over-diagnosis and over-treatment of indolent prostate cancer [6], resulting in 
some cases of high risk prostate cancer being treated conservatively with active surveillance, or 
first step intervention with radiation or radical prostatectomy. It is imperative to the respective 
disparate patient populations to receive the most accurate, timely, prognostic diagnosis.
The national cancer institute (NCI) dictionary of cancer terms defines biomarker as a “biologi-
cal molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnor-
mal process, or a condition or disease.” Advancements in the field of biomarker discovery 
have shaped the way medicine is performed and patients are diagnosed [7]. Biomarkers are 
used throughout the scope of clinical progression from early detection and diagnosis through 
clinical endpoint determinations.
Ideal biomarkers should have high sensitivity and specificity. That is, the power to correctly 
identify a high proportion of true cases, or those that will experience an event - in this case, 
developing prostate cancer. A biomarker should also have high specificity, correctly identify-
ing patients who are truly negative for harboring prostate cancer. Typically, a balance is met 
between specificity and sensitivity. These results are presented as receiver operating charac-
teristic (ROC) curves which are a visual means to describe the statistical ability of a model to 
correctly classify cases from non-cases [8]. Complete random distribution creates an “area 
under the curve” or AUC value of 0.50, graphed as a straight slope line, while the value from 
a perfect prediction model would be 1.0. A reliable prediction model therefore should have 
an AUC value nearing 1.0.
Here we will discuss the scope of biomarkers currently used for prostate cancer diagnosis, 
as well as prognosis to aid in disease monitoring and treatment oriented decision-making. 
Prostate cancer biomarkers are currently among three categories: blood, tissue or urine based 
biomarkers.
2. Blood-based biomarkers
An ideal biomarker screen is non-invasive. Blood collection is considered a minimally inva-
sive technique with quick turnaround time that is also indicative of real-time alterations and 
disease states in the body, while robust or stable enough for findings to be reproducible across 
clinics. For prostate cancer as with many other diseases, the use of blood to monitor disease 
progression was the first and hallmark analysis performed to detect the disease.
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In recent years, the phrase “liquid biopsy” has been coined, expanding a simple blood draw 
into an extensive cancer screen, testing for circulating tumor cells or circulating tumor free 
DNA in the blood. These tests have shown great promise in detecting cancer at early stages 
across a wide array of malignancies including prostate cancer [9].
Today, we continue to use blood based screens as means to detect prostate cancer, inform 
patients and clinicians on necessity of treatment, as well as to plan and monitor treatment 
response.
2.1. Prostate-specific antigen
The discovery of prostate and prostatic fluid associated antigens, most notably prostate-
specific antigen (PSA) occurred in 1970 by Richard Ablin [10]. PSA is a glycoprotein produced 
by human kallikrein-3 (hK3), a member of a class of highly homologous serine proteases, the 
tissue kallikreins. PSA is normally produced by the epithelial cells of the prostate gland and 
secreted into the lumen to aid in liquefaction of semen ejaculate. However, other pathological 
conditions in the prostate, such as benign prostatic hyperplasia (BPH) or prostatitis can ele-
vate the serum PSA levels, resulting in a “false positive” PSA test. PSA concentration in blood 
has been heavily explored for detection of prostate cancer, as well as treatment response and 
progression free survival monitoring thereof.
The number of diagnosed prostate cancer cases surged with the implementation of PSA 
screening tests, peaking at around the time of its approval by the United Stated Food and Drug 
Administration (FDA) in 1994 for prostate cancer detection. While PSA is prostate specific, it 
is not, however, specific to cancer, being additionally increased in the aforementioned benign 
prostate conditions. Since its discovery, PSA has been extensively studied in randomized clini-
cal trials as a screening test for prostate cancer. Despite this discovery, prostate cancer remains 
the most commonly diagnosed non-cutaneous cancer in men in the United States, with solid 
tumor-associated deaths only second to lung cancer [1]. In addition to poor cancer specificity, 
PSA also has low sensitivity. Reported in the prostate cancer prevention trial (PCPT) 15% of 
men with PSA 0–4 ng/ml have prostate cancer, 15% of those are high Gleason score [11, 12].
Ultimately, implementation of PSA as a screening tool led to an over-diagnosis and subse-
quent over-treatment of low-risk disease. Perspective studies indicated up to 10% of patients 
who received curative therapy by either radical prostatectomy or radiation were over-treated 
[13]. In 2012 The United States Preventative Services Task Force (USPSTF) recommended 
against PSA based screening for prostate cancer [14]. This recommendation has recently been 
amended to suggest PSA may be used specifically in men 55–69 on a case-by-case basis with 
informed patient consent regarding potential harms of screening. In all, the usefulness of PSA 
will continue to persist especially in disease monitoring, but recent advances lose faith in PSA 
alone as a diagnostic tool. In-depth analysis of PSA has revealed several molecular variations 
and functions of PSA which may prove to be more specific to cancerous tissues.
2.1.1. Free vs. bound PSA
PSA is typically observed complexed to protease inhibitors such as alpha 1-antichymotrypsin 
(ACT) or alpha 2-macroglobulin, known as bound PSA [15, 16]. Discovered in the 1990s, a 
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higher ratio of free PSA, that is, not bound to protease inhibitors and considered inactive, is 
associated with increased likelihood of BPH rather than cancer [15, 17–19]. Specific assays have 
also been developed to measure bound PSA (complexed-PSA), which is usually PSA-ACT and 
is elevated in cancer [20]. A percentage free PSA (free PSA/total PSA) can be calculated, and is 
typically lower in men with prostate cancer [21], where early studies linked <25% free PSA to 
detection of prostate cancer with a sensitivity of 95% [22]. However, follow-up analyses have 
had less promising results likely due to the relative instability of free or uncomplexed PSA 
compared to bound, making this an unreliable clinical parameter for patient diagnosis [23, 24].
2.1.2. Proenzyme PSA (proPSA)
Free PSA can be found in three different forms; proenzyme PSA (proPSA), benign PSA 
(BPSA) and intact PSA. proPSA is found increased in patients with prostate cancer [25, 26]. 
Several isoforms exist of proPSA based on varying truncations including [−2] and [−4] proPSA. 
[−2] proPSA or p2PSA has shown promise as a prostate cancer biomarker as it is not detected 
in BPH, and in trials increased the AUC from 0.52 for PSA or 0.53 for percentage free PSA 
to 0.73 [27]. [−2] proPSA has been used preferentially to total or free PSA for prostate cancer 
detection or biopsy [28–30].
2.1.3. Prostate-specific antigen density (PSAD) test
The PSAD test attempts to add specificity to PSA testing in prostate cancer by determining the 
amount of PSA produced in relation to size of the gland, as size has been highly correlated 
with prostate cancer prognosis [31, 32]. Prostate size can be measured with magnetic reso-
nance imaging or transrectal ultrasound by a physician. High density indicates that a small 
volume prostate is responsible for making a large amount of PSA, and reflective of prostate 
cancer. In contrast, low density reflects an enlarged prostate, most likely due to BPH that is 
responsible for the PSA elevation.
2.1.4. PSA velocity
Another factor suggested to provide more accuracy to PSA in ability to predict prostate can-
cer lies in the rate at which increase is observed, referred to as PSA velocity. PSA testing 
is performed at routine intervals in men on active surveillance, and elderly men at risk of 
developing prostate cancer. Elevated PSA is considered in the range of 4.0–10.0 ng/ml, though 
prostate cancer may still be found in men below this range. PSA velocity factors the rate of 
PSA increase over time, such that an increase greater than 0.5 ng/ml per year may be indica-
tive of prostate cancer [33].
2.2. The prostate health index
The Prostate Health Index (PHI) is an intuitive formula based upon utilization of several well 
characterized PSA forms—total PSA, free PSA, and [−2] proPSA or p2PSA, such that:








The PHI’s multifactorial approach has compounded the precision of each of the PSA measu-
rements providing one patient score, shown to drastically increase the specificity for prostate 
cancer [28, 34]. PHI has been approved by the FDA for men with PSA in the 4.0–10.0 ng/ml 
range.
Several clinical trials have retrospectively performed direct comparison to PHI against other 
early detection biomarkers across blood or urine analysis. In a European cohort of men under-
going either an initial or repeat biopsy, comparing PHI to PSA or free PSA, PHI increased the 
AUC values to 0.70 compared to 0.65 or 0.53 respectively [35]. In one prospectively performed 
trial it was determined that 30.1% of patients who underwent a biopsy could have been spared 
the painful procedure based on PHI score [36]. PHI has additionally been compared against 
urine biomarkers (to be discussed further in this chapter), with PHI increasing AUC over 
PCA3 or TMPRSS2:ERG [35, 37]. While results were similar, PHI was the only one correlated 
with Gleason grade greater than 7 [38].
2.3. The four-Kallikrein panel and 4Kscore® test
The four-kallikrein panel, subsequently referred to as the 4Kscore test is a reflex, or follow-
up blood test for men who have an abnormal PSA or digital rectal exam (DRE) result and 
are being considered for an initial or repeat prostate biopsy after a prior negative biopsy 
result. True to its name, the test is based upon inclusion of four–kallikreins, total PSA, intact 
PSA, free PSA in addition to human kallikrein-2 (hK2). The test is generated by OPKO Labs 
(Nashville, TN) and has been marketed as accurately identifying the risk of aggressive pros-
tate cancer (Gleason >7) in a subsequent biopsy or radical prostatectomy, aiding in patient 
action plan–based decision making.
The first clinical report of the four-kallikrein panel was among 740 previously unscreened 
men who underwent biopsy for a PSA above 3.0 ng/ml in the European Randomized Study 
of Screening for Prostate Cancer [39]. Subsequent studies have been performed for at least 
10 cohorts totaling over 15,000 subjects (reviewed in [40]), each of which observed an AUC 
between 0.80 and 0.90 for the four-kallikrein testing. Results from these studies consistently 
demonstrate the four-kallikrein panel effectively identified high-grade disease while reduc-
ing the number of unnecessary biopsies 49–57% among men being screened for the first time. 
The 4 k panel is the only test, aside from PSA that has been linked to long-term end-points 
including prostate cancer metastasis [17, 41]. Studies were initially performed in Europe, and 
limitations include only retrospective analysis, in primarily white populations with an alter-
native Gleason scale used. In translation to the United States to incorporate FDA guidelines, 
modifications of the test were implemented with positive results.
2.4. Stockholm-3
The Stockholm 3 model (S3M) is a combination of blood biomarkers initially including PSA, 
free PSA, intact PSA, hK2, MSMB, MIC1, genetic polymorphisms (SNPs) and other variabilities 
such as age, family history, previous prostate biopsies or exam [42, 43]. Later algorithm modi-
fication replaced intact PSA with HOXB13 [44]. The goal of the study was to increase the accu-
racy of high-risk prostate cancer diagnosis. S3M was tested in over 100,000 men, 50–69 years 
of age with no diagnosis of prostate cancer in Stockholm, Sweden [42, 43]. The performance 
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of S3M was compared to PSA alone. The use of S3M was found to decrease the number of 
biopsies by more than 50%, avoid negative biopsies and significantly improve the detection of 
high-risk prostate cancer [42, 43].
2.5. Prostate-specific membrane antigen
Prostate-specific membrane antigen (PSMA) is another glycoprotein with enzymatic function 
uniquely expressed in the prostate. As its name suggests, what makes it unique from PSA is 
that it is not a secreted protein, rather it is an integral membrane protein. Yet, like PSA, PSMA 
is also not specific to prostate cancer.
While PSMA has had little success as a serum based diagnostic marker, it is now being used as the 
target of an FDA approved radiographic scan (ProstaScint) in which an antibody against PSMA 
(7E11) is linked to a radiographic agent 111indium. ProstaScint increased predictive value for 
metastatic prostate cancer, identifying positive lymph node metastases [45]. Several new PSMA 
specific tracers have been developed for use in PET and PET/CT scanning with performance 
characteristics that exceed those of ProstaScint and are likely to be approved soon for clinical use.
2.6. Prostatic acid phosphatase
Prostatic acid phosphatase (PAP), or prostatic specific acid phosphatase (PSAP) is a glycopro-
tein enzyme secreted by prostate cells like PSA. Discovered in the 1930s as a diagnostic bio-
marker [46], it was replaced with the discovery of PSA in the 1970s. However, PAP reemerged 
following the discovery that PAP was highly expressed in correlation with tumor staging, and 
is the target of the first prostate cancer immunotherapy, Sipuleucel-T, approved by the FDA 
in April, 2010 [47, 48], and which increased overall survival of men with metastatic prostate 
cancer in its first IMPACT trial [49].
2.7. AR-V7
Androgen receptor splice variant 7 (AR-V7) is a splice variant of androgen receptor (AR) that 
lacks the ligand binding domain leading to its constitutive transcriptional activity indepen-
dent of androgens. Due to its androgen independent function, AR-V7 has been implicated in 
the resistance to second-generation anti-androgen therapies. AR-V7 can be detected in circu-
lating tumor cells (CTCs) and its presence is correlated with resistance to second generation 
anti-androgens including enzalutamide and abiraterone [50, 51]. These results suggest the use 
of AR-V7 as a treatment selection biomarker.
3. Tissue-based biomarkers
Tissue based prognosticators are among the most diverse in functionality. Tissue based assays 
can be performed from as little tissue as a single core of a biopsy up to radical prostatectomy. 
Yet, these assays are the most invasive due to the nature of tissue extraction through surgi-
cal resection or biopsy. Patients may undergo one or multiple sets of biopsies in the course 
of disease detection and active surveillance. Biomarker screening may also be performed on 
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patients post radical prostatectomy to predict treatment response, recurrence free survival and 
likelihood of disease progression. Many of these tests are commercial panels available to ana-
lyze multiple mRNA signatures in the prostate, but recent advancements in protein and cancer 
epigenetics are expanding the possibilities of prostate cancer prognosis. Assays are monitored 
by The National Comprehensive Cancer Network (NCCN), an alliance of U.S. cancer centers 
directing clinical practice guidelines, as well as the Food and Drug Administration (FDA).
Here we will discuss several of the most commonly used tests:
3.1. DNA
Deoxyribonucleic acid (DNA) is the genetic material of all living things. In comparison to other 
cancers, prostate cancer has little in the way of genetic mutations. Researchers have used the 
several well described genomic alterations to their advantage as prognosticators of disease.
3.1.1. Epigenetic testing
Current biopsy strategies sample areas of the prostate in a gridded fashion in attempt to have 
the most representative assessment of the prostate. Even with this strategy in place, less than 
1% of the prostate is sampled. As less than one-third of biopsies return positive results for 
cancer, there is large concern over inconclusive biopsy results.
The field cancerization effect was first observed in the 1950s when it was noticed that tis-
sues surrounding cancerous lesions contained markers associated with tumor development 
of oral squamous-cell carcinoma [52]. This phenomenon has since been observed in most 
solid tumors. Further understanding of the concept is explained in [53]. Today, field effect 
can translate to modifications in cellular morphology, epigenetics, genomic or mitochondrial 
DNA alterations, and changes in gene expression or protein levels (reviewed in [54]).
One such assay, ConfirmMDx, tests the epigenetic field effect by observing the molecular 
changes in methylations occurring in prostate cancer. DNA methylation is among the most 
common measures of epigenetic abnormality, and easiest to test. These alterations are 
not detectable in histological analyses, but visible with methylation specific PCR (MSP). 
Biologically these methylations may be responsible for silencing of key tumor-suppressive 
genes critical to preventing cancer development, and because of the cancer field effect, this 
test dramatically amplifies the tested area of the prostate. ConfirmMDx is recommended for 
men having undergone an initial negative biopsy.
Prostate cancer-associated epigenetic biomarkers used in this assay include glutathione 
S-transferase-Pi (GSTP1), APC and RASSF1. Methylation of GSTP1 is among the most com-
mon somatic alterations observed in prostate cancer with high specificity and sensitivity, and 
which correlates strongly with Gleason score, age, PSA and DRE [55–57].
3.1.2. PTEN loss and ERG rearrangements
Phosphatase and tensin homolog (PTEN) is a tumor suppressor commonly lost in many 
cancers. Loss of PTEN is one of few genomic alterations occurring in prostate cancer. PTEN 
deletion associates with poor outcome and is an established prognostic biomarker for prostate 
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cancer. Analysis of prostatic tissue by Immunohistochemistry (IHC) or Fluorescence in situ 
hybridization (FISH) demonstrated that PTEN loss is associated with prostate cancer bio-
chemical recurrence, disease progression and metastasis [58–63].
TMPRSS2:ERG fusion is found in ~50% of prostate cancer [64, 65]. TMPRSS2:ERG is a result of 
gene rearrangement and fusion between androgen regulated transmembrane protease, serine 
2 (TMPRSS2) and ERG transcriptional factor genes [64, 65]. This leads to significant overex-
pression of ERG reported to promote prostate cancer oncogenesis [66–70]. TMPRSS2-ERG 
rearrangements are accompanied by PTEN loss, which cooperates to promote prostate cancer 
progression [69, 70]. Moreover, loss of PTEN and presence of TMPRSS2:ERG fusion together 
predict prostate cancer biochemical recurrence [71] and Metamark further provides screening 
for loss of PTEN and ERG rearrangement in their PTEN/ERG screen.
3.2. mRNA
Messenger RNA or ribonucleic acid (mRNA) is genetic material carrying information between 
DNA and protein.
3.2.1. The genomic prostate score
Oncotype DX offers a diverse array of genomic health testing including breast, colon and 
prostate cancer. The Genomic Prostate Score (GPS) is a prostate specific array which aids in 
decision-making between initiating immediate treatment or active surveillance. The test mea-
sures expression from 12 genes in four prostate cancer associated biological pathways: andro-
gen signaling (AZGP1, FAM13C, KLK2, SRD5A2), cellular organization (FLNC, GSN, GSTM2, 
TPM2), stromal response (BGN, COL1A1, SFRP4) and cellular proliferation (TPX2), as well as 
5 reference genes (ARF1, ATF5E, CLTC, GPS1, PGK1) [72]. This assay has been validated pro-
spectively as an independent predictor of tumor aggressiveness based on adverse pathology, 
and death associated with prostate cancer and metastasis [73, 74]. GPS is advised for patients 
with low-risk clinical prostate cancer (very low, low or intermediate NCCN risk). AZGP1 was 
further validated as a potential biomarker for significant disease [75]. Loss of AZGP1 assessed 
by RNA in situ hybridization and immunohistochemical analysis is associated with worse out-
come and overall survival [75].
3.2.2. Prolaris
Prolaris is a prognostic genetic test developed by Myria Genetic Laboratories based on a 
46-gene expression signature strongly tied to cell cycle progression genes. Uniquely paired 
with cellular proliferation and Gleason grading, The Prolaris Score is generated as a metric 
of an individual’s prostate cancer aggressiveness. This score provides a relative risk among 
patients of the same risk group defined by the American Urological Association (AUA), and a 
10-year prostate cancer specific mortality risk in men with localized disease [76].
3.2.3. Decipher
The Decipher Biopsy was generated from GenomeDX, based on whole genome technology. 
In men with localized prostate cancer undergoing biopsy or radical prostatectomy, this test 
divides patients into Low Risk or High Risk, aiding clinicians and patients in decision making 
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toward active surveillance or intensification of treatment with multi-modal therapies. Decipher 
Biopsy measures 22 RNA biomarkers to correlate the probability of clinical metastasis within 
5 years following radical prostatectomy [77] and is predictive of lymph node metastasis [78]. 
This test can be performed on either biopsy or prostatectomy samples reproducibly [79].
3.3. Protein
3.3.1. ProMark
ProMark is the first protein based prognostic test for prostate cancer from Metamark Genetics 
Inc. Based on the understanding that mRNA levels may not be completely reflective of a dis-
eased state, ProMark assays protein levels in intact, formalin fixed biopsy samples to infer prog-
nostic information about the patients’ condition at the time of biopsy. Based on a quantitative 
multiplex immunofluorescence (QMPI) platform in which tissues are fixed in formalin, samples 
are stained for eight protein markers for cancer and normal regions and quantified in situ [80]. 
Markers include SMAD4, PDSS2, HSPA9, FIS, pS6, and YBOX1 to designate regions of prostate 
cancer, as well as proteins found in tumor and benign tissues, DERL1 and CUL2. Selected by 
computational modeling, these combinations of protein markers reflect the morphology from 
tumor epithelium for reliable prognostication [80–82]. Cost to perform ProMark protein screen-
ing is additionally quite low compared to usual guideline-based care [83]. ProMark has been 
utilized in clinical studies to predict lethal outcome. The test is currently recommended for men 
with Gleason grade 3 + 3 or 3 + 4 prostate cancer as part of the NCCN Clinical Care Guidelines.
3.3.2. p63 and AMACR
p63 has been identified as a marker of basal cells in multiple epithelial tissues including nor-
mal prostate [84]. Significant downregulation or loss p63 is commonly observed in prostate 
cancer [84, 85]. Alpha-methylacyl coenzyme A racemase (AMACR) is commonly found over-
expressed in prostate cancer and exhibits little to no expression in the normal prostate tis-
sues [86–89]. A combination of high-molecular weight cytokeratins, AMACR and loss of p63 
can be used to define normal prostate tissues, prostate intraepithelial neoplasia and prostate 
adenocarcinoma [90, 91].
4. Urine biomarkers
Urine analysis is a non-invasive screening technique for prostate cancer.
4.1. PCA3
Prostate cancer antigen 3 (PCA3) (also known as DD3) is a non-coding mRNA specifically 
expressed in human prostate tissues, and highly overexpressed in prostate cancer [92].
The Progensa PCA3 assay is an FDA approved urine based molecular test to aid in repeat 
biopsy decisions from Hologic [93]. Following DRE, a simple “first-catch” urine test captures 
prostate epithelial cells released into the urine. PCA3 mRNA levels are quantified in propor-
tion to PSA. Also included in the NCCN’s Clinical Practice guidelines for prostate cancer early 
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detection, this test’s specificity lies in PCA3 which is highly upregulated in prostate cancer cells 
and not affected by instances of benign prostatic hyperplasia (BPH), prostatitis or other condi-
tions as is the case for PSA. PCA3 testing is currently FDA approved for men previously having 
a negative biopsy with a persistently elevated PSA to help identify men who need a repeat 
biopsy. PCA3 is calibrated to identify men at low risk for a positive biopsy such that PCA3 < 25 
indicates that it is safe to forgo the biopsy. Increase in score was directly correlated with likeli-
hood of positive repeat biopsies, and predictive of 4-year biopsy outcome [94–96]. PCA3 has 
subsequently been explored and proven to positively predict detection of prostate cancer in 
initial biopsies with high specificity and may aid in initial biopsy decision making [97, 98].
4.2. SelectMDX
Utilizing first catch post-DRE urine, SelectMDx tests for mRNA levels of genes DLX1 and 
HOXC6. Analysis for this test incorporates multifactorial data from PSA density and prior 
biopsy data to increase significance of this liquid biopsy. This test has shown promise over 
PCA3 in two prospective clinical trials in identification of patients with high-grade prostate can-
cer (AUC of 0.90 in first cohort and 0.86 in validation cohort) [99]. SelectMDx was recently added 
to the European Association of Urology’s list for added decision making before a repeat biopsy.
4.3. TMPRSS2:ERG
As ERG rearrangements occur at the genomic level, prostate cancer associated gene fusions 
such as TMPRSS2:ERG rearrangements are also detectable in patient urine [71, 86–89]. Urine 
TMPRSS2:ERG was found to associate with Gleason score and tumor size in a large multi-
center study with 1312 men [100]. This strategy utilizes transcription mediated amplification 
(TMA) assay to quantify TMPRSS2-ERG mRNA normalized to PSA mRNA. Additionally, it 
was demonstrated that the combination of urine TMPRSS2:ERG with urine PCA3, improves 
the performance of serum PSA for predicting prostate cancer risk [100–102].
4.4. Mi-prostate score (MiPS)
The Michigan Prostate Score (MiPS) combines serum PSA levels with urine analysis for 
TMPRSS2:ERG and PCA3 mRNA as a predictive model for a positive prostate cancer biopsy. 
This compounded analysis of three independent prostate markers are closely correlated with 
presence of prostate cancer in an initial or repeat biopsy and provides a more accurate predic-
tive model of biopsy detected prostate cancer [101].
4.5. Extracellular vesicles
Exosomes are small extracellular vesicles secreted from cells ranging in size from 30 to 120 nm. 
A portion of the parent cell cytoplasm is contained inside each exosome for the biological func-
tion of cell-to-cell communication. For the purpose of clinical diagnostics, this mechanism can 
be manipulated to measure exosomal genetic material released into blood, urine or other bio-
logical fluids. RNA expression from tumor cells is promising as they are highly representative 
of cell of origin. As exosomes are secreted freely into the urine, exosomal based testing does 
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not require biopsies to detect oncogenic signatures [103, 104]. For instance, PCA3 and ERG 
mRNAs can be detected in exosomes and be predictive for high grade prostate cancer [105].
4.6. ExoDX prostate (IntelliScore)
Exosomal analysis of PCA3 and ERG RNA copy number from prostate cancer patient urine was 
determined to positively predict presence of high-grade prostate cancer [105, 106]. This test, 
now marketed as ExoDX Prostate(IntelliScore) is considered a liquid biopsy, combining urine 
with PSA screening from blood sample. Clinically, Prostate(IntelliScore) correctly predicts the 
occurrence of Gleason scores above 7, and has been recommended for men over 50 with PSA 
levels in the 2–10 ng/ml range. Further evaluation of this biomarker assay is currently underway.
New technologies are expanding to increase the capture and analysis for extracellular vesicles 
as experimental material. Exosome Diagnostics, who market the Prostate(IntelliScore) addi-
tionally provide isolation kids for exosomal RNA. Alternatively, devices such as the Exosome 
Total Isolation Chip (ExoTIC), have been generated specific for the high-yield isolation of 
extracellular vesicles from biofluids (blood, urine, and lavage), even allowing for separation 
among vesicles based on size. This work has initially been applied to protein and microRNA 
analysis, increasing the scope of assayable markers for prostate cancer [107].
5. Conclusions
Assays and technologies have vastly improved prediction strategies for recurrent prostate 
cancer and metastatic disease. Collectively, the biomarkers and assays presented within this 
chapter represent great advances in the diagnosis and prognostic assessment of patients with 
prostate cancer and aid in decision-making for subsequent treatment strategies (reviewed in 
Table 1). However, even with this extensive armamentarium there is still improvement to be 
made in risk-stratification to accurately identify patients with cancer, and among them, those 
at risk of developing high grade disease. As biomarkers become available it is increasingly 
important to understand how these tests are helpful to know when and on which patients 
these tests should be utilized. Guidelines for care are consistently monitored by urological 
associations globally. While recommendations vary based on country and among individual 
institutions and providers, more than ever, patient led decision making is at the forefront of 
screening. This was evidenced by USPSTF’s recent removal of PSA screening for healthy men 
as routine procedure, instead recommending individualized decision-making by physician 
counseling of patients as to the potential risks of inaccurate diagnosis leading to over-treatment.
Human nature understandably dictates a need for testing to be as minimally invasive as possible 
to eliminate painful procedures, and increase patient compliance and willingness to participate 
in early disease screening. The development of non-invasive screening methods such as blood 
and urine assays to limit prostate biopsy aids in reducing painful, and in the case of prostate 
cancer, often unnecessary procedures. This is even further amplified when taken into account 
the number of men who have to undergo the biopsy procedure repeatedly in the course of diag-
nosis and disease progression. The future of cancer screening, and hopefully diagnosis will come 
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from less invasive procedures. One such advance may be the implementation of imaging strat-
egies such as multi-parametric magnetic resonance imaging (mpMRI) to locate and diagnose 
prostate cancer. Offered prior to biopsy, patients with negative results are spared the biopsy, 
while those with cancerous lesions can undergo a targeted biopsy aided by mpMRI, minimizing 
Table 1. Screening assays for prostate cancer, classified by specimen and genetic material tested, invasiveness of the 
assay, clinical uses, biomarkers tested, and status of FDA approval. Certain tests have been proven exempt from FDA 
regulations, and these are also specified. The Clinical Laboratory Improvement Amendments (CLIA) certifies clinical 
laboratory developed tests to perform additional testing.
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complications, and obtaining accurate biopsies with ample cancer tissue to aid in treatment 
plan determination. This technique has tested more accurate than standard of care transrectal 
ultrasound (TRUS) biopsy in predicting presence of aggressive prostate cancer [108]. The role of 
imaging in prostate cancer diagnosis is still evolving and these technologies stand to introduce 
new avenues to the field of prostate cancer diagnosis and even treatment which may lead to 
better patient risk-stratification with increased survival rates of aggressive prostate cancer.
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